Clinical Trial Update: Is CYP24A1 Heterozygosity a Risk Factor for Nephrolithiasis?

View source ↗

Summary

A clinical trial sponsored by Hospices Civils de Lyon is investigating whether CYP24A1 heterozygosity is a risk factor for nephrolithiasis (kidney stones); the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephrolithiasis

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Nephrolithiasis | Status: NOT_YET_RECRUITING